Lost in Translation

Thursday, October 4, 2012

Missing Reports: Research Biopsy in Cancer Trials

›
A growing number of drug trials are collecting tissue to determine whether the drug hits its molecular target.   These studies...
1 comment:
Monday, August 20, 2012

Targeted Cancer Drugs: The "Price of Progress"?

›
S o here is the party line on the newest generation of cancer drugs.  Unlike older generation drugs, which are generalized poisons, newer...
3 comments:
Wednesday, May 2, 2012

Registration of Trials: A Census

›
Apologies to the millions of avid followers of Lost in Translation for the long haitus.  In response to an international petition campaign...
Monday, March 21, 2011

Tea Leaves: Predicting Risk and Benefit in Translation

›
E very early phase trial begins with a series of predictions: that a new drug will show clinical utility down to road, that risks to study v...
2 comments:
Tuesday, February 8, 2011

Dirty Windows of Drug Development

›
T hink of clinical trial data as a window on the efficacy and safety of a drug. Think of data protection and trade secrecy as soot. The abov...
1 comment:
Monday, December 20, 2010

More Gray Matter: Parkinson's Disease and Gene Transfer

›
S everal groups are pursuing gene transfer strategies against Parkinson's disease. No small task, because for these approaches to work, ...
Monday, November 29, 2010

Icarus, again: Adversity in another Gene Transfer Trial

›
Two weeks ago brought good news and bad news for gene transfer. First the good news. New England Journal of Medicine beatified a new ge...
›
Home
View web version

Biographical Information

Jonathan Kimmelman
I am Associate Professor of Biomedical Ethics at McGill University. My research centers on the ethics and policy of drug development. I spend my spare hours roaming through cities, in search of strange and mostly inconspicuous artifacts that are amenable to cataloging.
View my complete profile
Powered by Blogger.